Benita Nagel
CEO/Co-Founder
Nuntius Therapeutics
Nuntius Therapeutics develops transformative mRNA therapies for life-threatening diseases by integrating proprietary delivery technology, machine learning, and advanced nucleic acid engineering. The company utilizes programmable, non-immunogenic nanocarriers capable of superior tissue and cell targeting beyond the liver. Their pipeline currently focuses on advancing genetic medicines for indications in cancer, lung diseases, and neurodegeneration.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$125KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current mRNA therapies face challenges in delivering genetic payloads to specific tissues and cell types, often resulting in limited efficacy and potential off-target effects. Existing delivery technologies struggle to efficiently target cells beyond the liver, hindering the development of mRNA-based treatments for a wide range of diseases.
Solution
Nuntius Therapeutics develops programmable mRNA therapies using proprietary, non-immunogenic nanocarriers designed to enhance delivery efficiency to a wide range of tissues and cell types. The company leverages machine learning models to predict carrier quality and performance, guiding the selection of optimal candidates from a library of millions of distinct carriers. Nuntius also focuses on superior nucleic acid engineering to design mRNA with enhanced protein expression levels compared to existing mRNA therapeutics. This approach enables the development of transformative mRNA therapies for life-threatening conditions, including cancer, lung diseases, and neurodegenerative disorders.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing mRNA-based therapeutics for cancer, lung diseases, and neurodegenerative disorders.
Features
- Proprietary nanocarriers for targeted delivery of mRNA to specific tissues and cell types
- Non-immunogenic nanocarriers to minimize adverse immune responses
- Machine learning models to predict carrier quality and performance
- Superior nucleic acid engineering for enhanced protein expression levels
- Scalable nanocarrier production for efficient manufacturing